GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK
Approach
Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).
Advantage
We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our investors.
Our Portfolio



















































News
News
Antios Therapeutics Raises $96 Million in a Series B Financing
By Sixty Degree Capital |
Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and Life Sci Venture Partners and participating existing investors Lumira Ventures,…
Read More Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
By Sixty Degree Capital |
GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase…
Read More Arcellx Announces Executive Appointments
By Sixty Degree Capital |
Dr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical…
Read More